CLINICAL STUDY

Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot study

Desiree Kronawitter, Louis J Gooren1, Hendryk Zollver, Patricia G Oppelt, Matthias W Beckmann, Ralf Dittrich and Andreas Mueller

Department of Obstetrics and Gynecology, Erlangen University Hospital, Universitätsstrasse 21–23, D-91054 Erlangen, Germany and 1Department of Endocrinology, Free University Medical Center (VUMC), 1007-MB Amsterdam, The Netherlands

(Correspondence should be addressed to A Mueller; Email: andreas.mueller@uk-erlangen.de)

Abstract

Objective: It has been reported that hypoactive sexual desire disorder (HSDD) affects one-third of transsexual women (defined as postoperative male-to-female transsexuals) receiving estrogen replacement whose bioavailable androgen levels are lower than in ovulating women and comparable with those in surgically postmenopausal women. The aim of this study was to evaluate the efficacy of transdermal testosterone treatment and of oral dydrogesterone in transsexual women with HSDD receiving estrogens.

Methods: Seven transsexual women with HSDD were treated with a testosterone patch and nine transsexual women with HSDD were treated with oral dydrogesterone over 24 weeks. The primary end point was the change in the brief profile of female sexual function (B-PFSF) score. Secondary end points were changes in hormonal parameters and side effect assessments.

Results: A significant increase in total testosterone and free testosterone levels was observed in the group receiving transdermal testosterone. At 24 weeks, there was a significant improvement in the B-PFSF score showing an improvement in sexual desire among transsexual women treated with the testosterone patch, whereas no change in the B-PFSF score was observed in transsexual women treated with oral dydrogesterone. No side effects were reported.

Conclusions: In this pilot study, sexual desire in transsexual women improved significantly after treatment with the testosterone patch, without noticeable side effects.

European Journal of Endocrinology

Introduction

It has recently been reported that one in three transsexual women (defined as postoperative male-to-female transsexuals) receiving estrogen replacement suffers from hypoactive sexual desire disorder (HSDD) (1). It is now widely believed that testosterone has a role in female sexual desire (2–4). The role of testosterone in motivational aspects of sexuality such as sexual desire (5, 6) and activity (7) is now well documented. It is therefore possible that a lack of testosterone production and, in addition, the effect of continuous estrogen treatment in producing a marked increase in sex hormone-binding globulin (SHBG), binding adrenal androgens, might induce a state of severe hypoandrogenemia and might lead to symptoms of HSDD in these women.

We have reported previously that the levels of total testosterone (TT) and (as the level of SHBG significantly increases) calculated free testosterone (cFT) declined by up to 97% in transsexuals treated with estrogens (8–10). In addition, it has been reported that two out of three transsexual women have FT levels below the concentrations found in ovulating women (11). However, no significant correlation between androgen levels and measures of sexual desire have been detected in transsexual women and control women (1, 12). Despite this, there is ample evidence that treatment with testosterone increases sexual desire and activity in surgically menopausal women with HSDD (13–19). In some studies, statistically significant correlations have been observed between changes in sexual desire and testosterone serum concentrations after treatment with a testosterone patch (13, 14). Women suffering from low libido in the natural menopause may also benefit from testosterone treatment while taking estrogens (20, 21) or not taking estrogens (22). Some transsexual women wish to receive treatment with a progestational compound, as they believe that addition of this female hormone will bolster the feminization process, but
there is no evidence in support of this contention (23). Depending on their chemical structure, synthetic progestins have partial androgenic or anti-androgenic properties, but dydrogesterone is devoid of androgenic or anti-androgenic action.

This aim of this pilot study was to evaluate the effect of testosterone and of medication with a progestin on sexual desire in transsexual women with HSDD, using the brief profile of female sexual function (B-PFSF), which was developed and validated to provide good discrimination between women who have HSDD and those who do not (24).

Subjects and methods

Patients and sex hormone treatment

In our department, transsexual women who had undergone surgical sex reassignment (SRS) were normally treated with 10 mg i.m. estradiol-17β (E2) valerate every 2 weeks (Estradiol-Depot 10 mg; Jena-pharm, Jena, Germany). Routine monitoring of our patients in the first year after SRS: all of transsexuals were interviewed regarding their medical history and were tested for HSDD using the B-PFSF questionnaire 1 year after their initial SRS. None of them analyzed for this study was suffering from thrombosis or other vascular diseases. Transsexual women with complications in their postoperative period and those who were not satisfied with the aesthetic and functional results after SRS were not included in the analysis. Patients receiving other medications were also not included. All of the patients continued their normal diet throughout the observation period. Thereafter, the study population consists of 64 transsexual women. All transsexual women had their SRS in the years 2006 and 2007. A B-PFSF score ≤ 20 reportedly indicates clinically relevant HSDD (24). Some transsexual women were treated with a transdermal patch administering testosterone at 300 µg/day (Intrinsa TTS, Procter & Gamble Pharmaceuticals; Darmstadt, Germany) or others with oral dydrogesterone 10 mg/day (Duphaston 10 mg; Solvay Arzneimittel, Hanover, Germany), depending on their own preference. No randomization was done. The patients were monitored over a 24-week period and were seen every 12 weeks for clinical evaluation. They all underwent regularly monitoring, including hormonal analysis every 24 weeks, complete blood count, and serum chemistry profile, and transsexuals with significant abnormalities in any of these parameters were not included in the analysis. Any other necessary medical intervention was recorded and documented. At the end of the study period after 24 weeks, all of the participating transsexual women were evaluated again using the B-PFSF. All data files were evaluated anonymously and analyzed retrospectively. Institutional review board approval was obtained.

Hormone measurements

Before and after the 24-week study period, blood was sampled in the morning between 0800 and 1000 h to measure serum levels of LH, FSH, TT, DHEAS, estradiol (E), prolactin (PRL), and SHBG. In addition, the blood count, serum chemistry profile, and liver enzymes – aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transferase, cholesterol, and triglycerides – were regularly measured using routine clinical chemistry assessment.

All blood samples were immediately assayed for hormone parameters in a routine laboratory test using established commercial assays routinely monitored by participation in external quality control programs. All of the assays were carried out in a routine diagnostic endocrine laboratory. TT, DHEAS, SHBG, E, PRL, LH, and FSH were measured with chemiluminescent enzyme immunoassays (Immulite 2000; Siemens Medical Solutions Diagnostics Ltd, Bad Nauheim, Germany), as previously described in detail (25–32). For the TT-assay, the intraassay coefficients of variation (CV) were 16.3, 11.7, and 10.0% at the levels of 0.93, 2.98, and 5.26 nmol/l. The corresponding interassay CVs were 24.3, 13.0, and 10.3%.

Calculation of free testosterone

Measuring TT, and in particular FT, in women is challenging (33–35). cFT was calculated using the formula provided by the International Society for the Study of the Aging Male (http://www.issam.ch/free-testo.htm), from TT and SHBG in the same sample, as described in detail by Vermeulen et al. 1999 (34), without taking the albumin concentration into account (25, 27).

Brief profile of female sexual function

The B-PFSF consists of seven items, Table 1. Each item is scored on a 6-point Likert scale, from ‘always’ to ‘never’. The item scores were transformed (never = 0 points; always = 5 points) so that lower scores were indicative of poorer sexual function and higher distress. A total score for the B-PFSF is obtained by summing the scores for each item, resulting in a total score ranging from 0 to 35, while a cut-off of 20 was found to be clinically relevant in categorizing women as possibly having HSDD or not (24).

Statistical analysis

Numerical variables are presented as mean ± s.d., unless otherwise noted. Non-parametric statistical tests were used, which are based on ranks of observations and require no assumptions about the underlying distribution of data. Wilcoxon rank-sum tests were used to
Table 1  Age, body mass index (BMI), and change in sexual desire using the brief profile of female sexual function (B-PFSF) of the analyzed transsexual women treated with the testosterone 300 µg/day patch or with dydrogesterone 10 mg/day.

<table>
<thead>
<tr>
<th></th>
<th>Testosterone 300 µg/day</th>
<th></th>
<th></th>
<th>Dydrogesterone 10 mg/day</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline n = 7</td>
<td>24 Weeks n = 7</td>
<td>P</td>
<td>Baseline n = 9</td>
<td>24 Weeks n = 9</td>
<td>P</td>
</tr>
<tr>
<td>Age (years)</td>
<td>46.14 (12.94)</td>
<td>46.43 (12.70)</td>
<td>0.18</td>
<td>44.22 (6.18)</td>
<td>44.78 (6.16)</td>
<td>0.25</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.55 (6.42)</td>
<td>26.90 (6.35)</td>
<td>0.13</td>
<td>25.62 (3.28)</td>
<td>26.03 (3.42)</td>
<td>0.37</td>
</tr>
<tr>
<td>B-PFSF score</td>
<td>15.14 (3.38)</td>
<td>22.43 (3.64)</td>
<td>0.017*</td>
<td>16.57 (3.28)</td>
<td>17.00 (2.33)</td>
<td>0.43</td>
</tr>
<tr>
<td>Final items of the B-PFSF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I felt having sex</td>
<td>1.57 (0.53)</td>
<td>3.00 (0.82)</td>
<td>0.016*</td>
<td>2.33 (0.86)</td>
<td>2.11 (0.78)</td>
<td>0.55</td>
</tr>
<tr>
<td>I was unhappy about my</td>
<td>2.14 (0.69)</td>
<td>3.57 (0.53)</td>
<td>0.015*</td>
<td>2.67 (0.71)</td>
<td>2.56 (0.72)</td>
<td>0.76</td>
</tr>
<tr>
<td>lack of interest in sex</td>
<td>2.00 (0.58)</td>
<td>3.14 (0.38)</td>
<td>0.014*</td>
<td>2.56 (0.73)</td>
<td>2.44 (0.73)</td>
<td>0.78</td>
</tr>
<tr>
<td>Getting aroused took</td>
<td>2.71 (0.95)</td>
<td>3.71 (0.49)</td>
<td>0.020*</td>
<td>2.22 (0.44)</td>
<td>2.67 (0.71)</td>
<td>0.17</td>
</tr>
<tr>
<td>forever</td>
<td>2.43 (1.13)</td>
<td>3.43 (0.53)</td>
<td>0.023*</td>
<td>2.33 (0.50)</td>
<td>2.67 (0.50)</td>
<td>0.20</td>
</tr>
<tr>
<td>I felt disappointed by</td>
<td>2.57 (0.53)</td>
<td>3.29 (0.95)</td>
<td>0.025*</td>
<td>2.44 (0.73)</td>
<td>2.33 (0.50)</td>
<td>0.73</td>
</tr>
<tr>
<td>lack of interest in sex</td>
<td>1.71 (0.76)</td>
<td>2.14 (0.90)</td>
<td>0.046*</td>
<td>1.67 (0.50)</td>
<td>1.89 (0.33)</td>
<td>0.17</td>
</tr>
</tbody>
</table>

Data are shown as mean ± S.D. *Considered significant. No differences were found when baseline parameters of both groups were compared (P values were 0.69 for age; 0.71 for BMI; 0.52 for B-PFSF score; and 0.06; 0.16; 0.12; 0.19; 0.82; 0.70; 0.90, for the different items of the B-PFSF score).

Results

Of the 64 healthy middle-aged transsexual women who were evaluated for HSDD using the B-PFSF, 18 transsexual women turned out to have a B-PFSF score ≤ 20 and were categorized as having clinically relevant HSDD. This represents a prevalence of HSDD of 28% in the population studied. Two transsexuals were not included in the analysis because they changed their hormone medication. A total of 16 patient files were complete and were included in the analysis. Seven of the 16 women received treatment with the transdermal patch with testosterone 300 µg/day for a minimum of 24 weeks, while the other nine received oral dydrogesterone 10 mg/day for a minimum of 24 weeks. Changes in the anthropometric data and in the B-PFSF score are shown in Table 1. A significant increase in the B-PFSF score was observed in the transsexual women treated with the testosterone patch, while no changes occurred in the transsexual women treated with dydrogesterone. The hormonal profiles of both groups are shown in Table 2. A significant increase in TT and cFT levels was only observed in the group of transsexual women treated with the testosterone patch; no change was observed in the group treated with dydrogesterone. No differences were found when baseline parameters of both groups were compared. During the clinical evaluation every 12 weeks, no side effects were recorded in any of the transsexual women studied, and none of the participants discontinued the treatment. In the testosterone group six out of seven transsexuals (86%) continued the treatment after 24 weeks, while in the dydrogesterone group only four out of nine transsexuals (44%) continued the treatment after 24 weeks.

Table 2  Comparison of serum hormone levels of the analyzed transsexual women.

<table>
<thead>
<tr>
<th></th>
<th>Testosterone 300 µg/day</th>
<th></th>
<th></th>
<th>Dydrogesterone 10 mg/day</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline n = 7</td>
<td>24 Weeks n = 7</td>
<td>P</td>
<td>Baseline n = 9</td>
<td>24 Weeks n = 9</td>
<td>P</td>
</tr>
<tr>
<td>LH (IU/l)</td>
<td>5.44 (1.77)</td>
<td>5.69 (1.59)</td>
<td>0.59</td>
<td>4.24 (1.39)</td>
<td>5.20 (1.80)</td>
<td>0.17</td>
</tr>
<tr>
<td>FSH (IU/l)</td>
<td>3.66 (1.06)</td>
<td>3.94 (1.39)</td>
<td>0.89</td>
<td>5.61 (2.30)</td>
<td>6.51 (1.67)</td>
<td>0.44</td>
</tr>
<tr>
<td>TT (nmol/l)</td>
<td>0.54 (0.22)</td>
<td>2.35 (0.47)</td>
<td>0.018*</td>
<td>0.61 (0.39)</td>
<td>0.70 (0.39)</td>
<td>0.57</td>
</tr>
<tr>
<td>cFT (nmol/l)</td>
<td>0.0034 (0.002)</td>
<td>0.015 (0.002)</td>
<td>0.018*</td>
<td>0.005 (0.005)</td>
<td>0.009 (0.011)</td>
<td>0.26</td>
</tr>
<tr>
<td>DHEAS (µmol/l)</td>
<td>3.50 (1.75)</td>
<td>4.13 (2.00)</td>
<td>0.99</td>
<td>3.84 (1.38)</td>
<td>3.77 (1.37)</td>
<td>0.59</td>
</tr>
<tr>
<td>E (pmol/l)</td>
<td>680.71 (221.67)</td>
<td>699.58 (212.38)</td>
<td>0.55</td>
<td>708.86 (192.48)</td>
<td>711.44 (217.35)</td>
<td>0.95</td>
</tr>
<tr>
<td>Prolactin (mIU/l)</td>
<td>203.82 (86.33)</td>
<td>179.31 (54.45)</td>
<td>0.99</td>
<td>285.73 (158.37)</td>
<td>253.21 (140.69)</td>
<td>0.19</td>
</tr>
<tr>
<td>SHBG (nmol/l)</td>
<td>145.14 (27.56)</td>
<td>137.52 (22.25)</td>
<td>0.31</td>
<td>134.12 (44.46)</td>
<td>125.81 (45.57)</td>
<td>0.48</td>
</tr>
</tbody>
</table>

Data are shown as mean ± S.D. *Considered significant. No differences were found when baseline parameters of both groups were compared (P values were 0.15 for LH; 0.06 for FSH; 0.70 for TT; 0.51 for cFT; 0.67 for DHEAS; 0.78 for E; 0.23 for prolactin; and 0.57 for SHBG).
Discussion

To the best of our knowledge, this pilot study is the first to analyze the potential benefit of transdermal testosterone or oral dydrogesterone in the treatment of HSDD in transsexual women.

Using the B-PFSF to distinguish between women who have HSDD and those who do not, about 28% of the transsexual women in this study appeared to be suffering from HSDD. This finding is in agreement with the prevalence of HSDD among transsexuals reported in earlier studies (1), and remarkably it is also in accordance with the prevalence of HSDD reported in surgically postmenopausal women (36).

This study shows that testosterone therapy is effective in the treatment of HSDD in transsexual women receiving cross-sex hormone therapy with E2 valerate, while treatment with dydrogesterone had no observable effect. Efficacy was measured only for 24 weeks, which appears to be sufficiently long, as efficacy has previously been reported to reach a plateau at 24 weeks (37).

The levels of TT and cFT were significantly lower in transsexual women in comparison with ovulating women (1, 11). Transsexual women should therefore be compared with women after surgical menopause, who show similar testosterone levels. Previous studies have shown that women who had undergone surgical or natural menopause who were suffering from HSDD and were treated with a testosterone patch experienced a significant increase in sexual activity and desire (13–22). More than 85% of those who reported a benefit wished to continue testosterone treatment (21).

The findings of the present study are consistent with other studies that have shown that the side-effect profile of the testosterone patch appears to be acceptable to women receiving estrogen treatment and those who have undergone natural menopause and are taking estrogens with a progestin, as well as those being treated with testosterone alone (17, 19, 20, 22). Although the evidence of the potential benefit of testosterone treatment in women suffering from HSDD is very convincing, there has been a lack of such data for treatment options in transsexual women.

The present study also investigated the effects of dydrogesterone on HSDD, as some transsexual women strongly believe that progestins are a necessary addition to estrogens in their feminization process (23). Transsexuals often believe that treatment with progestins has positive effects on breast growth and libido, but to our knowledge there has been no scientific proof of this assumption. The use of progestin as part of the endocrine treatment regimen for male-to-female transsexuals is a matter of controversy, and a clinical effect of progestins has not been evident in small observational studies (38). However, advantages have been observed in some patients with abnormal psychological irritability and mammary tenderness (39). The present study did not provide any evidence that dydrogesterone had a positive effect on sexual desire among transsexual women.

In the follow-up of hormonal parameters in both groups, the levels of SHBG, LH, FSH, DHEAS, estradiol, and PRL showed no clear patterns of change over time. However, there was a significant increase in TT and cFT in the group of transsexuals treated with a testosterone patch. No side effects were reported in any of the transsexual women.

This investigation was a pilot study. Neither randomization nor blinding was performed. In addition, the number of transsexual women included was small, and the power of the study may be limited. Nevertheless, the use of a patch delivering 300 μg testosterone per day significantly improved sexual desire in transsexual women who were receiving cross-sex hormone therapy with E2 valerate, while treatment with dydrogesterone was not effective. Prospectively controlled and randomized studies are needed to provide greater insight into treatment options for HSDD in transsexual women and to investigate the potential risks of long-term use of testosterone. Furthermore, the clinical relevance of the changes in sexual desire has to be confirmed.

Declaration of interest

There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

Author contribution statement

Desiree Kronawitter: medical care of the patients, wrote the manuscript; Louis J Gooren: correction of the manuscript; Hendryk Zoller: medical care of the patients, patient files analysis; Patricia G Oppelt: medical care of the patients, patient files analysis; Matthias W Beckmann: medical care of the patients; Ralf Dittrich: laboratory methods; Andreas Mueller: wrote the manuscript, statistical evaluations.

References


Received 9 May 2009
Accepted 4 June 2009